A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)

Authors :: Viktor Grünwald
Alain Ravaud
Eric Angevin
J. Chang
Bernard Escudier
Andrea L. Harzstark
Daniel Castellano
Jürgen E. Gschwend
Yulei Wang
Chinjune Lin
Michael Shi
Source :: Journal of Clinical Oncology. 29:4551-4551
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 4551 Background: Dovitinib is a potent oral inhibitor of angiogenic factors, including the fibroblast growth factor (FGFR) and vascular endothelial growth factor receptors (VEGFR). Phase (ph) I of ...

Subjects :: Cancer Research
business.industry
VEGFR Inhibitor
Phases of clinical research
Fibroblast growth factor
Vascular endothelial growth factor
chemistry.chemical_compound
Oncology
chemistry
Fibroblast growth factor receptor
embryonic structures
Cancer research
Medicine
In patient
Receptor
Metastatic renal cell cancer
business

Full Text Access

Tools